LTX 401

Drug Profile

LTX 401

Alternative Names: LTX-401

Latest Information Update: 19 May 2016

Price : $50

At a glance

  • Originator Lytix Biopharma
  • Class Cancer vaccines; Peptide vaccines
  • Mechanism of Action Cell membrane structure modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatocellular carcinoma; Solid tumours

Most Recent Events

  • 16 Apr 2016 Preclinical trials in Solid tumours in Norway (Intratumoural) prior to April 2016
  • 16 Apr 2016 Pharmacodynamics data from phase trials in Hepatocellular carcinoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 16 Apr 2016 Preclinical trials in Hepatocellular carcinoma in Norway (Intratumoural) prior to April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top